Pediatric Gastroenterology

Pediatric GI is increasingly aligned with adult therapeutic advances while preserving developmental and growth-specific endpoints. Pediatric IBD now uses ustekinumab, vedolizumab, risankizumab, and upadacitinib with weight-based dosing supported by PK extrapolation studies. Eosinophilic esophagitis management has been transformed by dupilumab (FDA-approved down to age 1), with budesonide oral suspension as a steroid-sparing option. Celiac screening strategies, gluten challenge protocols, and the role of HLA-DQ2/DQ8 are revisited. Sessions also address pediatric MASLD, ARFID and feeding disorders, intestinal failure with teduglutide, and very-early-onset IBD genetic workup (IL10RA, XIAP).